Insider buying last 90 days
No open-market insider purchases were filed for AMPH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AMPH insider filing, plotted on the chart in Gekko.Open AMPH in Gekko
NASDAQ: AMPH
Amphastar Pharmaceuticals (AMPH) Stock Analysis & Forecast
Oct 12 close
$26.76+0.14 (+0.5%)
Gekko Brief
AI summaryOct 12 closeThis week’s coverage centers on analyst views rather than company developments. Argus lowered its target price for Amphastar to $27.00, while other pieces compared the company’s valuation and fundamentals to peers such as Enanta Pharmaceuticals, with one noting shares trading well above an estimated fair value figure. No product, deal, or regulatory news accompanied these items.
AMPH closed at $26.76, up 0.5%, sitting above both its 50-day ($23.21) and 200-day ($22.34) averages, with the 50-day above the 200-day. The GekkoIndex reads 51, placing the stock in the Neutral zone, down 3.3 over five days. Despite the uptrend, price remains 34.1% below Gekko Fair Value of $40.62, a gap that stands in contrast to consensus analyst targets, which average $22.50 across 6 firms with 5 hold ratings and 1 sell, implying -15.9% from current levels.
Amphastar reports earnings on 5 November 2026 after close, 23 days out and within a typical 20-trading-day holding window; its last report showed EPS of $0.80 against a $0.51 estimate, with a 2.7% reaction, and it has beaten estimates in 4 of the last 8 quarters, with an average absolute reaction of 11.7%. No insider, Congress, or unusual options activity appears in the current windows. Seasonally, the next 20 trading days have averaged a 4.6% gain over 5 years, positive in 4 of them.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Amphastar Pharmaceuticals price vs fair value
Close $26.76200-day averageGekko Fair Value $40.62
Amphastar Pharmaceuticals quick facts
- Market cap
- $1.18B
- P/E ratio
- 15.3
- Forward P/E
- —
- EPS, TTM
- $1.69
- Revenue, TTM
- $730.0M
- Profit margin
- 10.8%
- Dividend yield
- —
- Beta
- 0.90
- Volume
- 362,817 avg 540,468
- 1-year return
- +7.2%
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±9.1%
- 50-day average
- $23.21
- 200-day average
- $22.34
- Next earnings
- Nov 5 after close
- Shares outstanding
- 42.54M
Amphastar Pharmaceuticals swing-trade checklist
Amphastar Pharmaceuticals scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $26.76 is above the 50-day ($23.21) and 200-day ($22.34) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
51, Neutral
Reading 51 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
34.1% below
Price is 34.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.6% on average
From this point in the calendar, the next 20 trading days averaged +4.6% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Amphastar Pharmaceuticals stock chart and price history
Amphastar Pharmaceuticals closed at $26.76 on Oct 12, 2026, +7.2% over the past year, inside a 52-week range of $16.65 to $29.52.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +12.5%
- 3 months
- +42.3%
- 6 months
- +25.3%
- 1 year
- +7.2%
The full AMPH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AMPH in Gekko
Follow Amphastar Pharmaceuticals through every session
Put AMPH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AMPH in GekkoFree for 7 days. No credit card required.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals develops, manufactures and sells a range of generic and branded drugs, covering injectable, inhaled and intranasal forms. Among its better-known products are Primatene Mist, an over-the-counter inhaler for mild asthma relief, Enoxaparin for preventing and treating deep vein thrombosis, and Naloxone, used to reverse opioid overdoses. Its broader lineup also includes glucagon emergency kits, the diagnostic agent Cortrosyn, and Amphadase, a hyaluronidase injection that helps other drugs absorb and spread in the body.
The company works through two main segments, one covering finished pharmaceutical products and the other active pharmaceutical ingredients, and it also distributes recombinant human and porcine insulin API. Its finished-product lines stretch further into epinephrine injections for severe allergic reactions, lidocaine formulations, vitamin K1 injection for newborns, emergency syringes, morphine and lorazepam injections, and treatments such as neostigmine methylsulfate and isoproterenol hydrochloride. Customers span hospitals, clinics, other care facilities and physicians' offices, and the company sells into markets including the United States, China and France.
Amphastar was founded in 1996 and operates out of Rancho Cucamonga, California. Its shares are listed on the NASDAQ under the ticker AMPH.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- amphastar.com
Amphastar Pharmaceuticals GekkoIndex: the smart money zone
Amphastar Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 51, in the Neutral zone, down 3.3 points over five sessions.
51Neutral
Down 3.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 90 | −0.9% | +0.3% | ||
| Accumulation | 266 | 0.0% | −0.5% | ||
| Neutral (current zone) | 313 | −0.4% | −2.7% | ||
| Distribution | 9 | Too few readings yet | |||
| Selling | 4 | Too few readings yet | |||
Average AMPH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the AMPH price, zone by zone.Track AMPH in Gekko
Is Amphastar Pharmaceuticals stock overvalued? Gekko Fair Value
Amphastar Pharmaceuticals trades 34.1% below Gekko Fair Value of $40.62, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Amphastar Pharmaceuticals shares are worth, recalculated every trading day.
$40.62
Gekko Fair Value, Oct 10, 2026
34.1% Undervalued
At the end of Aug 2026 the price was 3.7% above the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open AMPH in Gekko
Amphastar Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Amphastar Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AMPH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AMPH, plotted on the chart in Gekko.Open AMPH in Gekko
Buybacks
Amphastar Pharmaceuticals has been buying back its own shares.
- Latest authorization
- $50.00M, Mar 16, 2026
- Bought back, quarter ended Jun 30, 2026
- $45.21M
- As a share of market cap
- 3.83%
- Trailing four quarters
- $145.4M
From company filings.
Amphastar Pharmaceuticals earnings: next date and track record
Amphastar Pharmaceuticals reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- $0.86
- Revenue estimate
- $197.9M
4 of 8reports beat the EPS estimate
±11.7%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Amphastar's Q2 2026 earnings call emphasized improved financial performance driven by revenue growth, margin expansion, and product launches. Revenue rose 5% year-over-year to $183.9 million with contributions from recent launches (e.g., Ipratropium Bromide HFA) and resilient demand for key branded products such as BAQSIMI and Primatene MIST. Profitability improved sequentially due to higher revenue, favorable product mix, and steps to mitigate duplicate 340B discounts. Management highlighted three strategic growth pillars: (1) expand branded/differentiated commercial portfolio, (2) advance complex generics and biosimilars, and (3) progress proprietary development programs. Operational updates included manufacturing expansion, continued shipments from the IMS facility despite an FDA warning letter and ongoing remediation, and a targeted approach to business development prioritizing near-term accretive assets. Pipeline updates noted recent product launches (iron sucrose, teriparatide), Ipratropium Bromide HFA sales (~$8.4M), and that AMP-004 (insulin aspart) remains on schedule for a 2027 commercial launch. During Q&A, management acknowledged headwinds—pricing pressures from 340B duplicate discounts affecting BAQSIMI, competition-driven declines in glucagon sales, and potential remediation actions at the IMS site—but expressed confidence in mitigation efforts and the company’s diversified model.
- Guidance
- Management provided qualitative forward-looking commentary rather than numeric guidance: expect a quarter similar to Q2 driven by higher BAQSIMI sales offsetting IMS-related costs; R&D expense is expected to tick up slightly as a percentage of sales; IMS is expected to continue shipping during remediation though some batches may face additional quality review and potential short-term delays; AMP-004 (insulin aspart) commercial launch is on schedule for 2027; business development focus prioritizes assets that are immediately accretive or accretive within ~1 year.
- Risks flagged
- IMS facility received an FDA warning letter and is undergoing remediation which could lead to slowed releases, extra quality reviews, and potential temporary shutdowns; pricing pressure from 340B duplicate discounts materially impacted BAQSIMI revenues and remains to be fully resolved; increased competition has caused a steep decline in glucagon sales and could pressure other products; general dynamic operating environment and reimbursement/discount dynamics that may affect average selling prices and margins.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $0.80 est $0.51 | $183.9M est $179.9M | +2.7% |
| May 7, 2026 | $0.42 est $0.71 | $171.2M est $173.5M | −20.5% |
| Feb 26, 2026 | $0.61 est $0.89 | $183.1M est $188.8M | −27.7% |
| Nov 6, 2025 | $0.93 est $0.83 | $191.8M est $190.5M | −5.1% |
| Aug 7, 2025 | $0.85 est $0.74 | $174.4M est $177.1M | +14.4% |
| May 7, 2025 | $0.74 est $0.69 | $170.5M est $173.1M | +3.3% |
| Feb 27, 2025 | $0.92 est $0.94 | $186.5M est $188.8M | −8.9% |
| Nov 6, 2024 | $0.96 est $1.00 | $188.8M est $192.1M | −10.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Amphastar Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Amphastar Pharmaceuticals is $22.50, −15.9% from the last close, from 6 firms rating the stock in the last 90 days.
$22.50consensus 12-month target, −15.9% from the last close
Now $26.76Avg $22.50
Low $20High $30
Each firm’s latest rating in the last 90 days: 6 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 2 | Wells Fargo | $20 | −25.3% |
| Aug 18 | Barclays | $23 | −14.1% |
| Aug 7 | Needham | $20 | −25.3% |
| Aug 7 | Piper Sandler | $20 | −25.3% |
| Aug 7 | Wells Fargo | $20 | −25.3% |
−2.7%average 20-day move after past Neutral readings
+4.6%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Amphastar Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Amphastar Pharmaceuticals averaged +4.6% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.6% | 4 of 5 |
| Next 10 trading days | +2.9% | 3 of 5 |
| Next 15 trading days | +3.9% | 3 of 5 |
| Next 20 trading days | +4.6% | 4 of 5 |
| Next 30 trading days | +6.7% | 4 of 5 |
For scale, AMPH’s typical 20-trading-day move in either direction is about 9.1%.
Amphastar Pharmaceuticals market cap and key statistics
Amphastar Pharmaceuticals’s market cap is $1.18B, with a P/E ratio of 15.3 and revenue of $730.0M over the last twelve months.
Valuation
- Market cap
- $1.18B
- P/E ratio
- 15.3
- EPS, TTM
- $1.69
- Gekko Fair Value
- $40.62
Trading
- Volume
- 362,817
- Avg volume, 20 days
- 540,468
- 52-week high
- $29.52
- 52-week low
- $16.65
- Shares outstanding
- 42.54M
Financials
- Revenue, TTM
- $730.0M
- Profit margin
- 10.8%
- Return on equity
- 10.3%
- Quarterly earnings growth, YoY
- +4.7%
Risk and income
- Beta
- 0.90
- Typical daily move
- ±3.7%
- Typical 20-day move
- ±9.1%
Amphastar Pharmaceuticals stock news this week
Coverage of Amphastar Pharmaceuticals this week reads negative: 1 positive, 0 neutral and 2 negative headlines.
- Amphastar Pharmaceuticals, Inc. (AMPH) Stock ForecastsYahoo! Finance Canada, Oct 8
- Amphastar Pharmaceuticals Inc Share Price - AMPH, RNS News, Articles, Quotes, & ChartsProactive financial news, Oct 7
- Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?Zacks Investment Research, Oct 6
- Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH)Defense World, Oct 6
- Amphastar Pharmaceuticals (NasdaqGS:AMPH) Stock PriceSimply Wall Street, Oct 5
Amphastar Pharmaceuticals peers
Amphastar Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Amphastar Pharmaceuticals stock FAQ
What is Amphastar Pharmaceuticals’s market cap?
Amphastar Pharmaceuticals’s market cap is $1.18B at the Oct 12, 2026 close of $26.76, with 42.54M shares outstanding. The shares trade on a P/E ratio of 15.3.
What is the Amphastar Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Amphastar Pharmaceuticals is $22.50, −15.9% from the last close. Of the 6 firms that rated the stock in the last 90 days, 0 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Amphastar Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Amphastar Pharmaceuticals is undervalued: the Oct 12, 2026 close of $26.76 is 34.1% below Gekko Fair Value of $40.62. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Amphastar Pharmaceuticals report earnings next?
Amphastar Pharmaceuticals is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of $0.86 per share on revenue of $197.9M. Amphastar Pharmaceuticals beat the earnings estimate in 4 of its last 8 reports, moving 11.7% on average across the report.
What is Amphastar Pharmaceuticals’s 52-week high and low?
Amphastar Pharmaceuticals’s 52-week high is $29.52 and its 52-week low is $16.65; it closed at $26.76 on Oct 12, 2026, +7.2% over the past year. Over the last five years the shares peaked at $67.66 on Aug 9, 2023.
Is Amphastar Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Amphastar Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.